drugset
drugset / Trial / NCT02291432

Autologous Cell Therapy for Stress Urinary Incontinence in Males Following Prostate Surgery

NCT02291432 ↗

Phase 1/2 Completed 25 enrolled Cook MyoSite
NaSingle-groupOpen-labelTreatment

Summary

To study the safety and potential efficacy of Autologous Muscle Derived Cells for Urinary Sphincter Repair (AMDC-USR) for the treatment of male stress urinary incontinence (SUI) for patients that have undergone prior prostate surgery.

Timeline

Start
2015-02-19
Primary completion
2019-06-28
Completion
2019-06-28

Drugs

EvaluationDrugModalityDoseRoute
Subject autologous muscle-derived cells (AMDC) Unknown — —

Indications

urinary system disorder